Bristol-myers Squibb Compnay

Bristol Meyers Squibb Company

Pratik Devasthale

Guohua Zhao

Hao Zhang

Sean Chen

Jon J Hangeland

Yoon T Jeon

Saleem Ahmad

Peter T Cheng

R Michael Lawrence

Wei Meng

Robert Paul Brigance

Huji Turdi

Wei Wang

Manoranjan Panda

William N Washburn

Xiang-Yang Ye

Kumaravel Selvakumar

Suresh Dhanusu

Susheel Jethanand Nara

Prasada Rao Jalagam

Fang Moore

Alicia Regueiro-Ren

Minsheng Zhang

Denis E Ryono

Shung C Wu

Charles Z Ding

Michael Frederick Parker

Peter T W Cheng

Arthur M P Doweyko

Todd J Friends

Lawrence R Marcin

Tamara Dejneka

Timothy F Herpin

Xiaojun Han

Johan Malm

Rita Civiello

Kishore V Renduchintala

Yolanda V Caringal

Swanee E Jacutin-Porte

Leatte R Guernon

Andrei Sanin

Susan Nicole Pieniazek

Radhakrishnan Sridhar

Palanikumar Balasubramanian

Jeffrey A Robl

Lawrence G Hamann

Chunjian Liu

Natesan Murugesan

John Matthew Fevig

Bruce A Ellsworth

Satheesh Kesavan Nair

Andres S Hernandez

Jianxin Feng

Dong Cheng

James Mignone

Murugesan Natesan

Wel Meng

Stephen P O'CONNOR

The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (Formula (I))

Small molecule inhibitors of galectin-3

The present disclosure relates to compounds of Formula (I) or Formula (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Small molecule inhibitors of Galectin-3

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to α-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of α-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

3-substituted propionic acids as αV integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of &#x3b1;-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as &#x3b1;V integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Cyclobutane- and azetidine-containing mono and spirocyclic compounds as &#x3b1;V integrin inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

3-substituted propionic acids as &#x3b1;V integrin inhibitors

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Aryl dihydropyridinones and piperidinone MGAT2 inhibitors

The present invention provides compounds of Formula (I): (Formula (I)), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to &#x3b1;v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of &#x3b1;v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Azole amides and amines as alpha v integrin inhibitors

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments. 

Substituted pyridinones as MGAT2 inhibitors

The present invention provides compounds of Formula (I):  or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Growing community of inventors

Plainsboro, NJ, United States of America

Pratik Devasthale